RxDoctor Payments Data

Jennifer Peters, NP

Family · Peoria, AZNPI 1679832943

Payments from drug & device makers

$5,038in general payments, 2019–2025

Across 244 payments — averaging $20.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$684
  • Lilly USA, LLC$491
  • Johnson & Johnson$373
  • Amgen$360
  • Indivior Inc.$341
  • Novo Nordisk$325
  • plus $2K from 34 others

What the payments were for

  • Food & beverage$5,038100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,038 in reported general payments places this provider in the 90th percentile of 4,119 family providers in Arizona.

See all family providers in Arizona

Medicare billing

Part B allowed, 2024
$99,009
Medicare patients
131
Services billed
1,829

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide51$72,732
FarxigaDapagliflozin Propanediol52$40,958
TrulicityDulaglutide35$39,662
JardianceEmpagliflozin12$13,309
TradjentaLinagliptin13$11,967
XareltoRivaroxaban14$11,491
Trelegy ElliptaFluticasone/Umeclidin/Vilanter15$9,995
LinzessLinaclotide16$4,205
Albuterol Sulfate HfaAlbuterol Sulfate101$3,106
Lantus SolostarInsulin Glargine,hum.Rec.Anlog13$1,944
Fluticasone-SalmeterolFluticasone Propion/Salmeterol16$1,824
Omeprazole83$1,782
Atorvastatin Calcium145$1,464
SynthroidLevothyroxine Sodium12$1,424
Gabapentin72$1,236

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$325$72,73251 claims
AstraZenecaFarxiga$684$40,95852 claims
Lilly USA, LLCTrulicity$491$39,66235 claims
Boehringer IngelheimJardiance, Tradjenta$174$25,27625 claims
Johnson & JohnsonXarelto$373$11,49114 claims
GSKTrelegy Ellipta$121$9,99515 claims
AbbVieLinzess, Synthroid$247$5,62928 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,119 family providers in Arizona.

Other family in Peoria

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →